Specialities

Specialities

Bladder Cancer
Breast Cancer
Colorectal Cancer
COVID-19
Dermatologic Cancers
Diagnostics and Screening
Gastrointestinal Cancers
Genitourinary Cancer
Gynecologic Cancers
Hematology
Hematologic Malignancies
Head and Neck Cancer
Immunotherapy
Leukemia
Lymphoma
Multiple Myeloma
Ovarian Cancer
Pancreatic Cancer
Lung Cancer
Prostate Cancer
Renal Cancer
Endocrine Cancers
Pediatric Oncology
Policy
Sarcoma
Supportive Cancer Care
Soft Tissue Tumors
Neuro-oncology
Pathology
Radiology
Radiotherapy
Rare Diseases
Search

Trending Topic
3 mins

Trending Topic
Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked

Foreword – touchREVIEWS in Oncology & Haematology, Volume 22, Issue 1, 2026

This issue of touchREVIEWS in Oncology & Haematology brings together a diverse collection of articles reflecting the growing complexity of cancer care and the continued evolution of precision medicine across tumour types. From rare malignancies and treatment-related challenges to emerging targeted therapies and novel biological insights, the contributions highlight both recent progress and the significant […]

Connect With Us:

Facebook
X (Twitter)
Instagram
Youtube
Linkedin
touchINFOGRAPHIC
Industry-Sponsored Content

Overcoming barriers to CAR T-cell therapy referral

Topics Covered:
Hematologic Malignancies
touchONCOLOGY

Check your Inbox

We've sent your certificate

Back to Activity
Close Popup
touchONCOLOGY

Thank you
for your Feedback!

Back to Activity
Close Popup

Video Navigation

Overview

CD19-directed chimeric antigen receptor (CAR) T-cell therapies have proven to be an important treatment option for certain hematological malignancies.1 However, many physicians apply the autologous stem cell transplantation (ASCT) eligibility criteria to CAR T-cell therapy referral, limiting the number of patients who could potentially benefit from access to treatment.1

Patient identification, timing of referral, and transitioning to post-treatment monitoring are key factors highlighted by experts that may improve CAR T-cell therapy referral.1 Age, performance status, disease status, cardiovascular function, pulmonary function, renal function, hepatic function, infections, and psychological health should not preclude patients from receiving referrals or further evaluation for CAR T-cell therapy.1 Timely referral should be made by the patient’s primary oncologist to specialists as soon as the disease becomes relapsed or refractory, and close collaboration between CAR T-cell therapy specialists and other medical disciplines allows CAR T-cell therapy to remain a feasible option for patients despite comorbidities.1

This infographic summarises the expert recommendations for unique CAR T-cell therapy patient eligibility and highlights referral practices with fewer restrictions compared with the ASCT eligibility criteria. To read the published paper please click here.

Learning Objectives

After reading this infographic, participants should be better able to:

  • Apply expert recommendations to promptly refer patients with indicated relapsed or refractory hematological malignancies to specialists for CAR T-cell therapy evaluation
  • Recognize that age, comorbidities, organ function and uncertainty about ASCT eligibility should not be used as strict exclusion criteria for referral
  • Understand that patient identification, timely referral and multidisciplinary collaboration can facilitate access to CAR T-cell therapy for eligible individuals

References

1

Shadman M, Ahmed S, Byrne MT, et al. Who Is Eligible for CAR T-Cell Therapy? Expert Perspectives on Overcoming Referral Barriers. Transplant Cell Ther. 2025;doi 10.1016/j.jtct.2025.10.025: 23 Oct [Epub ahead of print]

Video Navigation

Add a Note

Note Time: 00:00
Save Note
touchONCOLOGY
touchINFOGRAPHIC

This content is intended for healthcare professionals only.

Please confirm that you are a healthcare professional.

Continue
Decline

This activity is sponsored by Bristol Myers Squibb.

Bristol Myers Squibb provided financial support and has had input into the detailed project scope. This activity is provided by Touch Medical Communications (TMC) for touchONCOLOGY.

Close Popup
touchONCOLOGY

Could not verify Country/IP Address.

We were unable to verify your IP address, please try again later. If you are using a method to hide your IP address, such as a VPN or proxy, please disable this and try again.

Return to Homepage

This activity is sponsored by Bristol Myers Squibb.

Bristol Myers Squibb provided financial support and has had input into the detailed project scope. This activity is provided by Touch Medical Communications (TMC) for touchONCOLOGY.

Unapproved products or unapproved uses of approved products may be discussed; these situations may reflect the approval status in one or more jurisdictions. TMC has advised the sponsor to ensure that they disclose any such references made to unlabelled or unapproved use. No endorsement by TMC of any unapproved products or unapproved uses is either made or implied by mention of these products or uses in TMC activities. TMC accepts no responsibility for errors or omissions.

HE-US-2500780
Date of preparation: November 2025

Latest articles videos and clinical updates - straight to your inbox

Close Popup